1 min read
Recursion Aligns With FDA on Late-Stage Trial Design for REC-4881
Recursion described the program as an early example of AI-assisted drug discovery pursuing a design intended to support registration.

Recursion Pharmaceuticals said Nov. 18 that it aligned with the FDA on a late-stage trial design for REC-4881, a rare-disease therapy candidate.
Recursion described REC-4881 as an early example of AI-assisted drug discovery advancing toward a trial design intended to support registration.